These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Fertility drug use and the risk of ovarian tumors in infertile women: a case-control study. Asante A; Leonard PH; Weaver AL; Goode EL; Jensen JR; Stewart EA; Coddington CC Fertil Steril; 2013 Jun; 99(7):2031-6. PubMed ID: 23552324 [TBL] [Abstract][Full Text] [Related]
5. Use of fertility drugs and risk of ovarian cancer: results from a U.S.-based case-control study. Kurta ML; Moysich KB; Weissfeld JL; Youk AO; Bunker CH; Edwards RP; Modugno F; Ness RB; Diergaarde B Cancer Epidemiol Biomarkers Prev; 2012 Aug; 21(8):1282-92. PubMed ID: 22707710 [TBL] [Abstract][Full Text] [Related]
6. Risk for borderline ovarian tumours after exposure to fertility drugs: results of a population-based cohort study. Bjørnholt SM; Kjaer SK; Nielsen TS; Jensen A Hum Reprod; 2015 Jan; 30(1):222-31. PubMed ID: 25376453 [TBL] [Abstract][Full Text] [Related]
7. Fertility drugs and risk of epithelial ovarian cancer in Italy. Franceschi S; La Vecchia C; Negri E; Guarneri S; Montella M; Conti E; Parazzini F Hum Reprod; 1994 Sep; 9(9):1673-5. PubMed ID: 7836516 [TBL] [Abstract][Full Text] [Related]
8. Treatment for infertility and risk of invasive epithelial ovarian cancer. Parazzini F; Negri E; La Vecchia C; Moroni S; Franceschi S; Crosignani PG Hum Reprod; 1997 Oct; 12(10):2159-61. PubMed ID: 9402274 [TBL] [Abstract][Full Text] [Related]
9. A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Rossing MA; Tang MT; Flagg EW; Weiss LK; Wicklund KG Am J Epidemiol; 2004 Dec; 160(11):1070-8. PubMed ID: 15561986 [TBL] [Abstract][Full Text] [Related]
10. The risk of ovarian cancer after treatment for infertility. Bristow RE; Karlan BY Curr Opin Obstet Gynecol; 1996 Feb; 8(1):32-7. PubMed ID: 8777256 [TBL] [Abstract][Full Text] [Related]
11. Use of fertility drugs and risk of ovarian cancer. Diergaarde B; Kurta ML Curr Opin Obstet Gynecol; 2014 Jun; 26(3):125-9. PubMed ID: 24752005 [TBL] [Abstract][Full Text] [Related]
12. Assisted reproductive technology and ovarian cancer. Devesa M; Barri PN; Coroleu B Minerva Endocrinol; 2010 Dec; 35(4):247-57. PubMed ID: 21178919 [TBL] [Abstract][Full Text] [Related]
13. Risk of borderline ovarian tumors after fertility treatment - Results from a Danish cohort of infertile women. Kristensen AK; Frandsen CLB; Nøhr B; Viuff JH; Hargreave M; Frederiksen K; Kjær SK; Jensen A Gynecol Oncol; 2024 Jun; 185():108-115. PubMed ID: 38382167 [TBL] [Abstract][Full Text] [Related]
14. Parity, infertility, oral contraceptives, and hormone replacement therapy and the risk of ovarian serous borderline tumors: A nationwide case-control study. Rasmussen ELK; Hannibal CG; Dehlendorff C; Baandrup L; Junge J; Vang R; Kurman RJ; Kjaer SK Gynecol Oncol; 2017 Mar; 144(3):571-576. PubMed ID: 28108026 [TBL] [Abstract][Full Text] [Related]
15. Infertility and risk of fatal ovarian cancer in a prospective cohort of US women. Rodriguez C; Tatham LM; Calle EE; Thun MJ; Jacobs EJ; Heath CW Cancer Causes Control; 1998 Dec; 9(6):645-51. PubMed ID: 10189051 [TBL] [Abstract][Full Text] [Related]
16. Treatment for fertility and risk of ovarian tumors of borderline malignancy. Parazzini F; Negri E; La Vecchia C; Moroni S; Polatti A; Chiaffarino F; Surace M; Ricci E Gynecol Oncol; 1998 Mar; 68(3):226-8. PubMed ID: 9570970 [TBL] [Abstract][Full Text] [Related]
17. Fertility drug use and risk of ovarian tumors: a debated clinical challenge. Gadducci A; Guerrieri ME; Genazzani AR Gynecol Endocrinol; 2013 Jan; 29(1):30-5. PubMed ID: 22946709 [TBL] [Abstract][Full Text] [Related]
18. Reproductive characteristics in relation to ovarian cancer risk by histologic pathways. Merritt MA; De Pari M; Vitonis AF; Titus LJ; Cramer DW; Terry KL Hum Reprod; 2013 May; 28(5):1406-17. PubMed ID: 23315066 [TBL] [Abstract][Full Text] [Related]
19. Case-control study of borderline ovarian tumors: reproductive history and exposure to exogenous female hormones. Harlow BL; Weiss NS; Roth GJ; Chu J; Daling JR Cancer Res; 1988 Oct; 48(20):5849-52. PubMed ID: 3167840 [TBL] [Abstract][Full Text] [Related]
20. Ovarian cancer risk after the use of ovulation-stimulating drugs. Brinton LA; Lamb EJ; Moghissi KS; Scoccia B; Althuis MD; Mabie JE; Westhoff CL Obstet Gynecol; 2004 Jun; 103(6):1194-203. PubMed ID: 15172852 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]